Multiple sclerosis is a chronic, immune-mediated neurodegenerative disorder characterized by inflammation, demyelination, and gradual axonal degeneration within the central nervous system (CNS). While a range of disease-modifying therapies (DMTs) have been approved, many offer limited efficacy in slowing disease progression or preventing long-term disability, particularly in progressive forms of multiple sclerosis. Most current therapies act primarily on the peripheral immune system and have minimal impact on promoting central nervous system repair or providing neuroprotection, underscoring a significant unmet clinical need.
DelveInsight’s 2024 estimates indicate t...
